We continue our series in the Biologics campaign – now it is about the Epidermal growth factor receptor (EGFR).

At Chemspace EGFR proteins, RNAs, highly selective antibodies, and kits are available for purchasing on chem-space.com!

The epidermal growth factor receptor (EGFR) is the founding member of the large family of growth factor receptors carrying innate tyrosine kinase function. Over-activation of the EGFR is observed in a vast number of cancers including brain, lung, and other cancers. Targeting EGFR and its downstream signaling cascades is considered a rational and valuable approach in cancer therapy. Several synthetic EGFR tyrosine kinase inhibitors (TKIs) have been evaluated in recent years, mostly exhibited clinical efficacy in relevant models, and are now categorized into four generations. Due to resistance to the current TKIs new studies in finding more efficient EGFR inhibitors are needed.

You can find more information about the EGFR role in cancers here.

A recent article describes the identification and development of a mutant-selective, allosteric EGFR inhibitor for patients with EGFR-mutant lung cancer (LC). This drug candidate shows effectiveness across EGFR TKI-sensitive and resistant models with several EGFR mutations. Potentially it can be used as a single agent and in combination with other TKIs to specify more effective strategies in treating EGFR-mutant LC.

More information about this research is here.